A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at ...
Poly(ADP‐ribose) polymerases (PARPs) are a family of enzymes that play a crucial role in maintaining genomic integrity by detecting DNA damage and facilitating its repair. By catalysing the covalent ...
New findings show how inherited and acquired genetic mutations cause breast cancer resistance to CDK4/6 inhibitors.
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...
FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...
U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast ...
As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity decreases, scans show improvement, and patient lifespans are prolonged for some ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Liu is a ...
PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers. Niraparib approved for all-comers whose ...
How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results